. Matching criteria included VISN-2 hospital, hospital ward, prior hospital length of stay, age, and baseline platelet counts. The patients' electronic medical records were evaluated for symptoms consistent with ST and the Hunter serotonin toxicity criteria (HSTC) using an intensive, natural word search algorithm. The study included 251 matched pairs. Demographics and comorbidities were similar between groups. Over half of the study population received at least one concurrent medication with serotonergic activity. Receipt of agents with serotonergic activity was more pronounced in the vancomycin group, and the higher frequency was due to concomitant antihistamine and antiemetic use. Antidepressant use, including selective serotonin reuptake inhibitors (SSRIs), was similar between groups. No patients in either group were found to meet the criteria using the word search algorithm for ST. Fewer linezolid patients than vancomycin patients met the HSTC overall (3.2% versus 8.8%) and when stratified by receipt of a concurrent serotonergic agent (4.3% versus 12.4%). Of the patients meeting the HSTC, most had past or present comorbidities that may have contributed to or overlapped the HSTC. This study of hospitalized patients revealed comparably low frequencies of adverse events potentially related to ST among patients who received linezolid or vancomycin.
S
erotonin toxicity (ST), also often referred to as serotonin syndrome, is characterized by a triad of symptoms, including mental status changes, neuromuscular abnormalities, and autonomic hyperactivity. In addition to these symptoms, the patient must also have a temporal history of exposure to a drug known to have serotonergic properties. Signs and symptoms of ST appear anywhere from 1 h to several days after exposure to serotonergic agents (SAs), and clinical manifestations of ST range from barely perceptible to lethal (1, 2) . As a weak inhibitor of monoamine oxidase, linezolid has the theoretical potential to cause ST, especially when used in combination with adrenergic and SAs (1, 3, 4) . This precaution is reflected in the current linezolid package insert, which states that, "spontaneous reports of serotonin toxicity with co-administration of linezolid and serotonergic agents have been reported" and "where administration of linezolid and concomitant serotonergic agents is clinically appropriate, patients should be closely observed for signs and symptoms of serotonin syndrome" (5) .
Despite this risk, few comparative studies have evaluated the association between the use of linezolid and ST among patients concurrently receiving linezolid and medications with adrenergic and serotonergic activity (4, (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . To date, published postmarketing evaluations of the risk of ST in patients receiving concomitant linezolid and other serotonergic medications have been limited primarily to case reports and small retrospective studies without comparator groups (4, (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . While case reports and noncomparator cohort studies provide a glimpse into the causal relationship between drug exposure and effect, it is impossible to quantify the prevalence of the finding or the magnitude of the effect caused by a specific agent or a combination of agents. The most robust analysis to date is a comparison of ST between linezolid and comparators across 20 phase III and IV comparatorcontrolled clinical studies by Butterfield et al. (18) . In their review of the adverse event databases from those studies, which included 10,484 patients (5,426 treated with linezolid and 5,058 treated with comparators), Butterfield and colleagues (18) did not find enough evidence to conclude that linezolid-induced ST was different from that induced by comparators. No patients who received linezolid or the study comparator had an adverse event identified as ST. Furthermore, that analysis revealed comparably low proportions of potential ST in patients receiving linezolid and comparators when applying either the Sternbach criteria or Hunter serotonin toxicity criteria (HSTC) for diagnosis of ST; the Sternbach criteria and the HSTC are the two best-described criteria for defining ST in clinical practice (1, 2) .
Although these findings are reassuring, several considerations should be noted when interpreting these results. First, those authors relied on the adverse event databases from the original clinical trials. Because they were unable to access to the patients' original medical records, the positive and negative predictive values of the findings could not be assessed. Second, the adverse effect profiles of patients enrolled in clinical trials may not be fully reflective of the diverse patient populations who use the drugs in clinical practice. Therefore, comparative, patient-level analyses in the clinical arena are still needed to ascertain the "real-world" risk of ST, especially among patients receiving concomitant SAs. This analysis sought to fill this void in the literature by comparing the incidence of ST among hospitalized Veterans Affairs (VA) patients who received linezolid or vancomycin.
(This study was presented, in part, as a platform presentation at the 2012 IDWeek, a joint meeting of the IDSA, SHEA, HIVMA, and PIDS [19] .)
MATERIALS AND METHODS
Study design and population. A matched-cohort study was performed among hospitalized patients at the New York VA Health Care Network, or Veterans Integrated Service Network 2 (VISN-2), from January 2005 until February 2008. Patients on linezolid therapy for at least 1 day were matched 1:1 to those on vancomycin for at least 2 days. We purposefully made the entry criteria for vancomycin Ն2 days to avoid matching linezolid patients to patients who received vancomycin for only Ͻ24 h; there was a considerable number of "one-time" orders for vancomycin over the study period. We selected to include patients who received at least 1 day of linezolid treatment, since ST after the receipt of one dose of linezolid has been reported (20) . Matching criteria were (i) location at the start of therapy (intensive care unit [ICU] or non-ICU), (ii) admission hospital within VISN-2 (Albany, Bath, Buffalo, Canandaigua, or Syracuse, NY), (iii) length of stay (LOS) prior to initiation of therapy Ϯ 7 days, (iv) age (Ͻ50, 50 to 70, or Ͼ70 years), and (v) baseline platelet counts (Յ100,000 or Ͼ100,000 cells/mm 3 ). A random-number generator was used to select a patient match for the study in the event that multiple patients met the matching criteria.
Methods and procedure for collection of patient data. The pharmacy generated a list of patients from VISN-2 facilities who received linezolid or vancomycin. Clinical data for each patient who received linezolid or vancomycin across VISN-2 were obtained from the VISN-2 computerized patient record system (CPRS). The following data were collected: demographics, comorbidities (21) , hospitalization history, antibiotic therapy, disease severity (22, 23) , concomitant medications, microbiologic data, source of infection, and laboratory data.
The dose, route of administration, and duration of therapy for linezolid or vancomycin were recorded. All other medication usage was captured from 35 days prior to the start of linezolid or vancomycin therapy to 7 days after treatment discontinuation. Patients were reviewed for concomitant receipt of medications with serotonergic activity, and these included amphetamines and derivatives, analgesics, antidepressants (selective serotonin reuptake inhibitors [SSRIs], monoamine oxidase inhibitors, tricyclic antidepressants [TCAs], and others), antiemetics, antiepileptics, antihistamines, antiparkinsonians, antipsychotics, illicit drugs, migraine medications, weight loss drugs, and other miscellaneous agents (Table 1) (1, 4, 17, 18) .
The severity of illness at the initiation of therapy was captured by using the Acute Physiology and Chronic Health Evaluation II (APACHE-II) score (22) , based on the patient's worst physiologic score within the first 24 h of linezolid or vancomycin therapy. Laboratory values, complete blood count data, microbiologic culture data, and susceptibility data were recorded from 5 days prior to the initiation of linezolid or vancomycin therapy to 3 days after the discontinuation of therapy. The indication for treatment was categorized as bloodstream, urinary tract, skin and skin structure/osteoarticular, intra-abdominal, respiratory, or other/unknown infection. If a patient had multiple indications for therapy, the indication with the highest risk for mortality was used to classify the source of infection (24) .
Outcomes. Patients who received linezolid or vancomycin were evaluated for clinical signs of ST by using an intensive word search algorithm for ST and the HSTC (1), which are the most well-described criteria for defining ST in clinical practice. The safety analysis was performed in a stepwise manner using a natural word search algorithm similar to the one reported by Butterfield et al. (18) . We searched for adverse event terms starting 1 week prior to the initiation of linezolid or vancomycin until 1 week after discontinuation of either treatment to ensure that no cases of ST on therapy were missed due to mischarting of clinical data. The progress notes section from the patients' electronic medical records were first searched for the adverse event terms serotonin toxicity, serotonin syndrome, serotonin storm, hyperserotonemia, serotonergic syndrome, serotonin toxidrome, serotonergic, serotonin crisis, serotonin episode, and neuroleptic malignant syndrome and using a search string for all terms containing "serotonin." Next, the patients' electronic progress notes were searched for verbatim or exact terms of the HSTC during the same time frame (Table 2 ). A similar search was then done by utilizing synonyms or surrogate terms for the HSTC terms (1). Surrogate terms for HSTC were included due to the likelihood that a clinician may characterize a symptom specified in the criteria by a different term in the patients' electronic medical records. In addition, misspellings and abbreviations were included for all word search algorithms to minimize the likelihood of missing a potential ST case. For patients identified by either the exact or surrogate word search algorithm, a treatment-blinded review was performed to ensure that the adverse event criteria had been met during therapy with linezolid or vancomycin or within 1 week of therapy completion. Only cases that occurred during therapy with vancomycin or linezolid were considered. For the HSTC that involved Ͼ1 clinical symptom for meeting the criteria (e.g., ocular clonus and agitation or diaphoresis), symptoms had to occur within 2 days of each other while on therapy or within 7 days of completion of the study drug. The time period of 7 days posttreatment was a conservative estimate of the time that an event could be attributed to either agent (18) .
Data analysis plan. For the bivariate analyses comparing linezolid and vancomycin, categorical variables were compared by using the MantelHaenszel test for pair-matched data (McNemar's test), and continuous variables were compared by using the paired t test or the Wilcoxon matched-pairs test. The relationships between clinical and demographic characteristics and the occurrence of ST were compared by using Fisher's exact test for categorical variables and the Student t and Mann-Whitney U tests for continuous and ordinal variables, respectively.
To assess for the presence of effect measure modification, treatment-ST relationships were stratified by receipt of any SA, receipt of an antidepressant, and receipt of SSRIs. The 95% confidence intervals (CIs) were used to determine the heterogeneity/homogeneity of stratum-specific effect measures in each stratified analysis.
Since this was a matched-pair cohort study, conditional log-binomial regression was used to determine if treatment was independently associated with ST after adjustment for potential confounding variables (25) . Treatment interaction terms identified in the stratified analyses and all variables associated (P Ͻ 0.2) with ST and treatment were entered into the model. A manual backward approach was used to delineate the bestfitting or most parsimonious model. Potential confounding variables were retained in the final model if the resulting risk ratio (RR) for the treatment group changed by Ͼ10% in the absence of the confounder. All calculations were computed by using SAS version 9.3 (SAS, Cary, NC) and SPSS version 11.5 (SPSS, Chicago, IL).
RESULTS
During the study period, 298 hospitalized patients received linezolid for at least 1 day. Of these 298 patients, we were able to find Hypertonic, hypertonia, muscle rigidity, rigid, rigidity, spasm, spasticity, jaw trismus, and fever, hyperthermia, pyrexia, drug fever, intermittent fever, body temp increased, temp elevation, and ocular clonus, nystagmus, eye twitching, drooping eye, or clonus, myoclonus, twitching, muscle twitch, muscle twitching, rigidity vancomycin matches for 251 patients from a cohort of 2,408 patients on vancomycin therapy for Ն48 h. We were unable to find matches for 47 linezolid patients due to the lack of a match based on the following criteria: baseline platelet counts (n ϭ 20) and prior length of stay Ϯ 7 days (n ϭ 27). A comparison of matching variables and concurrent receipt of SAs is shown in Table 3 . Although we were able to successfully "caliper" match each linezolid patient to a vancomycin patient by prior length of stay Ϯ 7 days, the median prior length of stay was longer (P Ͻ 0.05) for the linezolid group than for the vancomycin group. All other matching criteria were identical between groups. The groups were relatively similar across key baseline covariates (Table 3) . However, several differences at a P value of Ͻ0.2 were observed. Patients who received linezolid were more likely (P Ͻ 0.2) to be hospitalized in the past 180 days, have decubitus ulcers, receive immunosuppressive agents, have a higher mean baseline platelet count, have an infection due to methicillin-resistant Staphylococcus aureus (MRSA) or Enterococcus spp., and have a bloodstream or urinary tract infection. Time at risk, reflected by a longer median duration of therapy, was also higher for the linezolid group than for the vancomycin group. Vancomycin was received, on average, for 10 Ϯ 9.7 days. In contrast, the total mean (standard deviation) time of linezolid treatment was 13.3 (12.1) days; the mean (standard deviation) times of oral and intravenous use were 8.5 (11.6) and 4.8 (8.0) days, respectively. Patients who received vancomycin had a higher frequency of alcoholism, a higher median number of comorbidities, and a higher frequency of respiratory tract infections. Concomitant receipt of agents with serotonergic activity was also more pronounced in the vancomycin treatment group. The higher frequency of SA use was driven primarily by antihistamines and antiemetics. Antidepressant use, including SSRIs and TCAs, was similar between groups. More patients in the vancomycin group received Ն2 agents with serotonergic activity than in the linezolid group (32.7% and 16.3%, respectively; P value of Ͻ0.001). The difference in the receipt of Ն2 SAs between treatment groups was due to the receipt of antihistamines and antiemetics. If only the receipt of agents with serotonergic activity other than antihistamines and antiemetics was considered, nearly identical proportions of patients in the vancomycin group relative to those in the linezolid group received Ն2 SAs (16.7% and 15.9%, respectively; P value of 0.8). Receipt of Ն2 antidepressants occurred in 6.8% of both treatment groups.
Overall, there were no reports of ST by any of the exact or surrogate word searches in either treatment group. Results of the HSTC word search algorithm are displayed in Fig. 1 . In total, 30 (6%) patients met HSTC by either the exact or surrogate word search. Eight (3.2%) linezolid patients and 22 (8.8%) vancomycin patients met HSTC (relative risk [RR] ϭ 0.36; 95% CI, 0.17 to 0.79; P ϭ 0.007). Results of the stratified analyses (concomitant receipt of an agent with serotonergic activity) are provided in Tables 4 to 6. For patients who did not receive a concomitant SA, similar proportions of patients in the linezolid and vancomycin groups were found to meet the definition of ST by the HSTC word search algorithm. Among those who received at least one SA, 4.3% of linezolid patients met the HSTC, while 12.3% of vancomycin patients met the HSTC by any word search algorithm. Of the 310 patients who received at least one SA, both members of a treatment pair received an SA in 93 instances. Among these 93 pairs, the risk of meeting the HSTC was lower among linezolid patients than among vancomycin patients (RR ϭ 0.31; 95% CI, 0.11 to 0.88). When stratified by concurrent receipt of antidepressants and SSRIs, a higher proportion of vancomycin patients than linezolid patients met the HSTC across all resultant strata. Of the 169 patients who received at least one antidepressant, both members of a treatment pair received an antidepressant in 22 instances. The risk of meeting the HSTC was lower among linezolid patients than among vancomycin patients among these concordant cases (RR ϭ 0.33; 95% CI, 0.07 to 1.65). Tables 7 (patients on linezolid) and 8 Table 3 . Variables found to be associated with ST by HSTC at a P value of Ͻ0.2 included hospital, residence in ICU, baseline platelet count, necessity of chronic dialysis, receipt of a medication with serotonergic activity, and receipt of SSRIs, antiemetics, antiepileptics, antiparkinsonians, and antipsychotics. Of these variables, only baseline platelet counts, receipt of any SA, and receipt of an antiemetic varied between treatment groups. In the conditional log-binomial regression, an association between linezolid and ST by HSTC remained (RR ϭ 0.45; 95% CI, 0.19 to 1.07; P ϭ 0.07) after adjustment for concurrent receipt of at least one SA (inclusion of a concurrent SA in the model was the only variable to change the RR by 10%).
DISCUSSION
Based on a lack of real-world comparator data on the risk of ST with linezolid, especially in patients receiving concomitant SAs (4, (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , the intent of this study was to delineate the risk of ST associated with linezolid relative to that associated with vancomycin among hospitalized patients. We selected vancomycin as the comparator since it is used for similar indications in clinical practice, and it is not known to cause ST (26, 27) . We opted to perform this study within VISN-2 because hospitalized VA patients have a higher frequency of conditions which elevate the risk for druginduced ST (1). Most notably, VA patients tend to receive more medications with serotonergic activity than other hospitalized patient populations (http://www.va.gov/vetdata/). In our study, more than half of the patients were receiving a medication with serotonergic activity, and many of them were on an antidepressant. An additional advantage of studying VA patients is that the VA system is a closed health care system. All patient data, both inpatient and outpatient records across the entire VA network, exist in a readily searchable electronic database. This feature is ideal when applying a natural search algorithm like the one used in this study and, most importantly, minimizes several types of information bias, including missing cases, incomplete case ascertainment due to loss to follow-up, outcome misclassification, and inconsistent charting practices.
By applying an intensive natural word search algorithm to the electronic medical records of this matched cohort, we were unable to find any notable differences in the risk of ST between agents. No cases of ST in the exact and surrogate ST word search algorithms were noted. A larger number of patients met the HSTC in the vancomycin group than in the linezolid group, and the differences were more pronounced among patients receiving medications with serotonergic activity. Upon closer inspection of these patients, it is unlikely that any of these patients actually experienced ST (Tables 7 and 8 ). One of the defining characteristics of ST by HSTC is clonus. As part of our natural word search algorithm, we used "rigidity" as a surrogate for clonus. This resulted in many patients, particularly in the vancomycin group, being classified as having ST by HTSC. Many patients who met HSTC by rigidity in the vancomycin group had longstanding conditions (e.g., Parkinson's disease) independent of their drug assignment, and this resulted in positive HSTC classifications. If one excludes rigidity Patient with history of dementia and multiple episodes of UTIs; patient had a complicated and prolonged hospital course; on multiple days of linezolid therapy, the medicine resident described his neck as rigid; there was no mention of rigidity in other medical notes Fentanyl (Ϫ9-EOT) HS Twitching (7), agitation (7), diaphoresis (6) Patient admitted with acute pancreatitis, complicated by severe acidosis, hypotension, renal failure, and ventilatory failure; on day 7 of linezolid treatment, a 30-s episode of twitching was noted during HD; this was also observed at 2 previous HD sessions; twitching was attributed to multiorgan failure and electrolyte abnormalities; agitation and diaphoresis in response to withdrawal of sedation medications were also in nursing notes Patient with advanced Alzheimer's disease who was admitted from nursing home with dehydration and decreased activity; on day 7 of linezolid, the kinesiotherapy note stated that his tone was rigid; this was the only mention of rigidity a Abbreviations: HD, hemodialysis; HS, Hunter surrogate; HE, Hunter exact; i.v. CRBSI, intravenous catheter-related bloodstream infection; PE, physical evaluation; SSTI, skin/soft tissue infection; UTI, urinary tract infection; EOT, end of treatment.
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December 2013 Volume 57 Number 12 aac.asm.org 5907 from the surrogate HSTC search, only 4 patients on linezolid (0.15%) and 11 patients on vancomycin (0.44%) met the criteria. Collectively, the findings failed to establish an increased risk of ST with linezolid relative to vancomycin among this highly vulnerable patient population. Several caveats should be considered when interpreting the findings of this paper. This was an observational study, and the natural word search algorithm was applied to existing data. Our findings are subject to all the caveats that are associated with this approach. Most notably, the major concern is the potential for prescribing bias due to a lack of randomization of treatment. In the case of our study, the concern is that prescribers would avoid using linezolid in patients perceived to be at risk for ST. While this is a reasonable concern, we do not believe that it is a major issue for our study. We purposely examined a time period when the potential risk of ST was not as well appreciated by clinicians. We also matched patients to ensure that they were as comparable as possible at baseline. When selecting matching variables, we selected covariates that not only would ensure that populations were similar at baseline but also minimized the potential for measureof-association distortions due to prescribing bias. Although the baseline platelet count is unlikely to be associated with risk of ST, we matched patients with this covariate since selection of linezolid or vancomycin for a given patient may be related to this covariate. Even with our intensive pairwise matching, concurrent receipt of SAs was still more pronounced in the vancomycin group. However, this higher usage among vancomycin patients was driven by antiemetics and antihistamines, medications not well recognized to cause ST in isolation (1) . Please note that much of the antihistamine and antiemetic use in the vancomycin treatment group was directly prescribed as prophylaxis against vancomycin-induced toxicity. The two groups received antidepressants and SSRIs in similar proportions, suggesting that prescribing bias was not a major factor contributing to the observed results.
It is also important to note that only 251 case pairs were evaluated. Since the incidence of ST with linezolid may be Ͻ0.4% (1/251), it is possible that our sample size did not allow us to fully delineate the associated risk of this adverse event. We do not believe that this negates the importance of our findings, since this is the first study to provide comparative information on the risk of ST with linezolid in the real-world setting. Rather, our findings highlight the need for further large-scale, comparative, real-world studies to further quantify the associated risk of this adverse event, particularly among patients receiving a concurrent SA. It is also important to realize that the sensitivity and specificity of HSTC are Ͻ100%. Surrogate terms were included in the natural word search algorithm to improve sensitivity, but it is possible, although unlikely, that a few cases were missed. If cases were missed, we anticipate that the misclassification error would likely be independent and nondifferential and thus would not bias the relative measures of associations.
Since the VA study largely involved only elderly men, the choice of study population may again limit the clinician's ability to generalize these results to other populations, namely, women. While we do not anticipate a markedly different threshold for ST between men and women, studies of women should be conducted to confirm this assertion. It is important to note that while there are always external validity concerns when studying VA patients, the VA population was an ideal study population for the research question because the relatively homogeneous patient population maximized internal validity. A more heterogeneous population might improve generalizability, but it would do so at the expense of internal validity by yielding too few patients across important confounders, ultimately resulting in unstable and biased measures of association.
In conclusion, after applying a sensitive and thorough word search algorithm to the electronic medical record data of hospitalized VA patients, we were not able to detect any increased risk of ST with linezolid relative to vancomycin. No patients were found to have ST by the exact or surrogate word search algorithm, and low rates of potential ST were found when applying the HSTC for ST. Of the patients meeting the HSTC, most had past or present comorbidities that may have contributed to or overlapped the reported adverse events. Our findings suggest that the theoretical potential for ST should not completely deter the use of linezolid in patients receiving another medication with serotonergic activity. Rather, clinicians need to be attentive in monitoring all patients receiving SAs, including linezolid, for ST, and the use of linezolid in a patient on an SA is a risk-versus-benefit situation. As it is possible that our sample size did not allow us to fully delineate the associated risk of this adverse event, our findings highlight the need for further large-scale, comparative, real-world studies to further quantify the associated risk of this adverse event, particularly among patients receiving a concurrent SA.
